Global pharma major Lupin Limited recently announced that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Apalutamide Tablets, 60 mg.
Approval is granted to market
Apalutamide Tablets, 60 mg, (RLD Erleada) had estimated annual sales of USD 1,185.5 million in the U.S., as per IQVIA MAT July 2023.
Source link
credite